Type 2 Diabetes: GLP-1 Mounjaro May Lower Heart Attack Risk
Who reported it (8)
- MACE Risk May Be Reduced with GLP-1 Drug in High-Risk Patients Inside Precision Medicine · 3d ago
- Obesity drug significantly reduces the risk of serious cardiovascular events and infections tum.de · 3d ago
- Claims Data Lend Support to Tirzepatide’s CV Effects in Patients With Diabetes TCTMD.com · 3d ago
- Tirzepatide lowers heart attack and cardiovascular event risk in adults with type 2 diabetes News-Medical · 3d ago
- Zepbound Lowers Heart Attack, Stroke Risk Among Type 2 Diabetics U.S. News & World Report · 3d ago
- Obesity drug significantly reduces the risk of serious cardiovascular events and infections Deutsches Zentrum für Herz-Kreislauf-Forschung · 3d ago
- GLP-1 drugs like Mounjaro may help lower heart attack risk by 33% Medical News Today · 3d ago
- Type 2 Diabetes: GLP-1 Mounjaro May Lower Heart Attack Risk Healthline · 3d ago broke it first
Momentum
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
Related trends
Column
A surge of August‑14 columns ties brain‑healthy habits to the future wellbeing of aging Americans
Blood Tests to Predict Alzheimer’s Are Causing Confusion and Distress
A breakthrough blood test promises earlier Alzheimer’s diagnosis, yet patients grapple with rising confusion and distress.
Column | 3 minutes of this activity may cut the risk of 13 cancers, study finds
A three‑minute burst of vigorous movement could slash the odds of thirteen cancers, upending the idea that only long workouts protect health.
Fact check: Trump makes numerous false and misleading claims about vaccines and autism
Recent coverage fact-checks numerous false vaccine and autism claims pushed by Donald Trump.
Why cyclospora keeps showing up in produce season after season
Utah reports nearly 50 cyclosporiasis cases, prompting local farmers to emphasize the importance of local produce.
Everyone's talking about hormone therapy for menopause. Should I be on it?
Hormone replacement therapy use has nearly doubled since 2017 amid new guidelines and widespread public discussion.